“Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s24. doi:10.25251/skin.1.supp.23.